#ES­MO22: Out­side liv­er can­cer, Keytru­da notch­es key win in neoad­ju­vant set­ting but flops in head and neck tu­mors

ES­MO in Paris is just get­ting start­ed, and ex­clud­ing a promi­nent miss in liv­er can­cer, Mer­ck is kick­ing things off with two ad­di­tion­al swings: a hit and a miss.

The Big Phar­ma is pre­sent­ing da­ta read­outs from two more stud­ies in­volv­ing pem­brolizum­ab, aka Mer­ck’s sales heavy­weight mar­ket­ed as Keytru­da. The im­mune check­point in­hibitor has been no­tably used by count­less oth­er com­pa­nies in com­bi­na­tion stud­ies with their own ex­per­i­men­tal drugs.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER